Fierce Pharma April 17, 2024
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner.
Medincell and AbbVie have struck up a co-development and licensing pact to create up to six long-acting injectables across “multiple therapeutic areas and indications,” Medincell said Tuesday.
Under the deal, Medincell is line to receive an upfront payment of $35 million, plus up to $1.9 billion in potential development and commercial milestones, as well as royalties on global sales.
Medincell will leverage its long-acting injectable technology platform to formulate new therapies and take them through the preclinical stage, at which point AbbVie will swoop in to finance and conduct clinical development of the...
Today's Sponsors
Today's Sponsor